Porvair Expands Its Operations at New Milton
Porvair Filtration Group, specialists in filtration and separation technologies, has announced the expansion of its UK facilities in New Milton near Christchurch. The new factory purchased this month will allow a consolidation of Porvair’s business in the UK and provides much needed manufacturing capacity to support the future growth of the business.
Porvair Filtration Group, whose parent company, Porvair plc, saw revenues grow by 10% last year, will consolidate its activities in the market for industrial filtration and separation products on the new site. Tom Liddell, Managing Director of Porvair Filtration Group commented: ‘At more than 40,000 sq ft, the new facility will allow us to integrate a number of activities within smaller units in the area, gaining efficiency in our operations and giving us space to sustain our growth. The investment is significant, but it is consistent with the sizeable growth opportunity we see for our products in the industrial process market.’
Porvair Filtration Group has supplied the process industry for more than 25 years, with innovative and performance driven filtration equipment (elements, cartridges and vessels). The process industry demands filters that can withstand the most extreme and aggressive conditions of temperature, pressure and corrosion, whilst safeguarding operators and systems from particulates and ensuring environmental protection. Each filtration and separation requirement presents its own critical challenges and requires superior reliability, durability and a robust product construction. Porvair Filtration Group provide highly specialised filtration solutions for use throughout the manufacturing process and have proven filtration solutions for the production of chemicals such as nitric acid, maleic anhydride, caprolactum, hydrogen peroxide, sulphuric acid, phosphoric acid, magnesium nitrate, as well as HDPE and LLDPE. By using the latest in metallic filter media technology, Porvair are able to provide improved performance, and reduced plant operating costs, enabling longer campaigns and greater materials recovery.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance